NZ611628A - Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients - Google Patents

Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Info

Publication number
NZ611628A
NZ611628A NZ611628A NZ61162811A NZ611628A NZ 611628 A NZ611628 A NZ 611628A NZ 611628 A NZ611628 A NZ 611628A NZ 61162811 A NZ61162811 A NZ 61162811A NZ 611628 A NZ611628 A NZ 611628A
Authority
NZ
New Zealand
Prior art keywords
laquinimod
improving
functional status
deterioration
multiple sclerosis
Prior art date
Application number
NZ611628A
Other languages
English (en)
Inventor
Nora Tarcic
Dan Bar-Zohar
Dina Kofler
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46162796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ611628(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NZ611628A publication Critical patent/NZ611628A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ611628A 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients NZ611628A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42074210P 2010-12-07 2010-12-07
US201161542996P 2011-10-04 2011-10-04
PCT/US2011/063460 WO2012078591A1 (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Publications (1)

Publication Number Publication Date
NZ611628A true NZ611628A (en) 2015-06-26

Family

ID=46162796

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ611628A NZ611628A (en) 2010-12-07 2011-12-06 Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients

Country Status (19)

Country Link
US (1) US20120142730A1 (https=)
EP (1) EP2648732A4 (https=)
JP (2) JP2013544887A (https=)
KR (1) KR20130124518A (https=)
CN (1) CN103260624B (https=)
AU (2) AU2011338647A1 (https=)
BR (1) BR112013014061A2 (https=)
CA (1) CA2820586A1 (https=)
CL (1) CL2013001602A1 (https=)
EA (1) EA201390827A1 (https=)
IL (1) IL250726A0 (https=)
MX (1) MX2013006464A (https=)
NZ (1) NZ611628A (https=)
PE (1) PE20140872A1 (https=)
PH (1) PH12013501193A1 (https=)
SG (2) SG190449A1 (https=)
UA (1) UA111959C2 (https=)
WO (1) WO2012078591A1 (https=)
ZA (1) ZA201304237B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884208B2 (en) * 2005-10-19 2011-02-08 Teva Pharmaceutical Industries, Ltd. Crystals of laquinimod sodium, and process for the manufacture thereof
ES2445451T3 (es) 2007-12-20 2014-03-03 Teva Pharmaceutical Industries, Ltd. Preparaciones estables de laquinimod
ME02414B (me) * 2009-07-30 2016-09-20 Teva Pharma Tretman kronove bolesti lakvinimodom
PT2467372T (pt) 2009-08-10 2016-08-23 Teva Pharma Tratamento de distúrbios relacionados com bdnf usando laquinimod
JP5819328B2 (ja) * 2010-03-03 2015-11-24 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドとメトトレキセートとの組合せによる関節リウマチの治療
CN102791130B (zh) * 2010-03-03 2015-02-25 泰华制药工业有限公司 使用拉喹莫德治疗狼疮肾炎
SG10201505236YA (en) 2010-07-09 2015-08-28 Teva Pharma Deuterated n-ethyl-n-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
CN106344576A (zh) 2011-10-12 2017-01-25 泰华制药工业有限公司 以拉喹莫德和芬戈莫德的组合治疗多发性硬化症
CN106063787A (zh) 2012-02-03 2016-11-02 泰华制药工业有限公司 拉喹莫德用于治疗一线抗TNFα疗法失败的克罗恩氏病患者的用途
HK1198296A1 (en) 2012-02-16 2015-03-27 Teva Pharmaceutical Industries Ltd. N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
TW201350467A (zh) 2012-05-08 2013-12-16 Teva Pharma Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
TW201410244A (zh) 2012-08-13 2014-03-16 Teva Pharma 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）
HK1211525A1 (en) * 2012-09-27 2016-05-27 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
US20140107154A1 (en) * 2012-10-12 2014-04-17 Teva Pharmaceutical Industries, Ltd. Laquinimod for reducing thalamic damage in multiple sclerosis
JP2015535287A (ja) 2012-11-07 2015-12-10 テバ ファーマシューティカル インダストリーズ リミティド ラキニモドのアミン塩
EA201591507A1 (ru) * 2013-02-15 2015-12-30 Тева Фармасьютикал Индастриз Лтд. Лечение рассеянного склероза лахинимодом
NZ630427A (en) 2013-03-14 2017-06-30 Teva Pharma Crystals of laquinimod sodium and improved process for the manufacture thereof
HK1220125A1 (zh) 2013-03-14 2017-04-28 Teva Pharmaceutical Industries Ltd. 拉喹莫德的透皮配方
TW201609098A (zh) * 2013-12-20 2016-03-16 泰瓦藥品工業有限公司 拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於延緩亨丁頓舞蹈症進展的用途
WO2015109083A1 (en) * 2014-01-17 2015-07-23 Teva Pharmaceutical Industries Ltd. Treatment of crohn's disease using low doses of laquinimod
EA201692180A1 (ru) * 2014-04-29 2017-08-31 Тева Фармасьютикал Индастриз Лтд. Лахинимод для лечения пациентов с рецидивирующе-ремиттирующим рассеянным склерозом (рррс) с высоким статусом инвалидизации
CN114699409A (zh) * 2014-10-16 2022-07-05 诺华股份有限公司 包含辛波莫德和拉喹莫德的用于治疗多发性硬化症的组合
EP3236964A4 (en) 2014-12-22 2018-09-19 Teva Pharmaceuticals International GmbH L-tartrate salt of pridopidine
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
AU2020316640A1 (en) * 2019-07-22 2022-03-03 Actelion Pharmaceuticals Ltd Methods of treating multiple sclerosis
CN110688373A (zh) * 2019-09-17 2020-01-14 杭州绿度信息技术有限公司 一种基于逻辑回归的offset方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006029411A2 (en) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
US20060205822A1 (en) * 2004-12-22 2006-09-14 Forest Laboratories, Inc. 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
RS52169B (sr) * 2006-06-12 2012-08-31 Teva Pharmaceutical Industries Limited Stabilni preparati lakvinimoda
EP2680006A1 (en) * 2007-02-08 2014-01-01 Biogen Idec MA Inc. Treatment for Amyotrophic Lateral Sclerosis
RS54328B1 (sr) * 2009-06-19 2016-02-29 Teva Pharmaceutical Industries Ltd. Tretman multiple skleroze lakvinimodom

Also Published As

Publication number Publication date
JP2017095476A (ja) 2017-06-01
WO2012078591A1 (en) 2012-06-14
CA2820586A1 (en) 2012-06-14
SG10201509831XA (en) 2015-12-30
EA201390827A1 (ru) 2013-12-30
SG190449A1 (en) 2013-07-31
CN103260624B (zh) 2015-06-03
ZA201304237B (en) 2014-08-27
PH12013501193A1 (en) 2013-07-15
WO2012078591A8 (en) 2012-08-02
CL2013001602A1 (es) 2013-10-25
AU2011338647A8 (en) 2013-09-05
UA111959C2 (uk) 2016-07-11
AU2017202055A1 (en) 2017-04-20
KR20130124518A (ko) 2013-11-14
EP2648732A4 (en) 2014-04-30
MX2013006464A (es) 2013-07-29
PE20140872A1 (es) 2014-08-09
AU2011338647A1 (en) 2013-07-04
CN103260624A (zh) 2013-08-21
JP2013544887A (ja) 2013-12-19
IL250726A0 (en) 2017-04-30
BR112013014061A2 (pt) 2016-09-13
US20120142730A1 (en) 2012-06-07
EP2648732A1 (en) 2013-10-16

Similar Documents

Publication Publication Date Title
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
MX2011013902A (es) Tratamiento de esclerosis multiple con laquinimod.
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
PH12014502447A1 (en) Use of high dose laquinimod for treating multiple sclerosis
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
NZ595941A (en) Treatment of neurodegeneration and neuroinflammation
RU2014109074A (ru) ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
NZ602510A (en) Treatment of lupus nephritis using laquinimod
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
NZ612717A (en) Treatment of pain associated with dislocation of basal endometrium
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2009004561A (es) Derivados de pirazolilo con actividad analgesica y utiles en el tratamiento o profilaxis del dolor.
NZ700824A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
JP2013541583A5 (https=)
NZ595376A (en) Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration
JP2013516493A5 (https=)
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
MX350195B (es) Analogos de cistamina para el tratamiento de la enfermedad de parkinson.
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
MD20140004A2 (en) Deuterated 1-piperazino-3-phenyl-indanes for treatment of schizophrenia
NZ602032A (en) Oral b12 therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2016 BY DENNEMEYER + CO

Effective date: 20151124

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2017 BY DENNEMEYER + CO

Effective date: 20161129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2018 BY DENNEMEYER + CO

Effective date: 20171122

LAPS Patent lapsed